Who is the manufacturer of VISULAS green?

Carl Zeiss Meditec filed the 510(k) submission for VISULAS green (K232051).

What is the FDA product code for VISULAS green?

HQF. It is classified under 21 CFR 886.4390 as a Class 2 device in the Ophthalmic panel.

What is the regulatory pathway for VISULAS green?

510(k) clearance (submission type: Traditional).

Who can help prepare an FDA 510(k) submission like VISULAS green?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

VISULAS green

K232051 · Carl Zeiss Meditec · HQF · Oct 24, 2023 · Ophthalmic

Device Facts

Record ID	K232051
Device Name	VISULAS green
Applicant	Carl Zeiss Meditec
Product Code	HQF · Ophthalmic
Decision Date	Oct 24, 2023
Decision	SESE
Submission Type	Traditional
Regulation	21 CFR 886.4390
Device Class	Class 2
Attributes	Therapeutic

Intended Use

VISULAS green is intended for use in photocoagulating ocular tissues in the treatment of diseases of the eye, including Photocoagulation of the retina Trabeculoplasty Iridotomy

Device Story

VISULAS green is an ophthalmic laser system for photocoagulation of ocular tissues using a 532 nm wavelength. The device operates in single-spot or multi-spot modes. Components include a laser console, touch control panel, foot switch, instrument table, and optional applicators (laser slit lamp or laser indirect ophthalmoscope). The system delivers thermal energy via continuous wave operation to cause tissue coagulation. It is used by clinicians in a clinical setting to treat retinal conditions, glaucoma (via trabeculoplasty/iridotomy), and other eye diseases. The provider uses the slit lamp or ophthalmoscope to visualize the target tissue and applies laser energy to achieve the desired therapeutic effect, benefiting the patient by treating ocular pathology.

Clinical Evidence

No clinical data. Substantial equivalence established through bench testing, software verification and validation, and compliance with electrical/laser safety standards (ANSI/AAMI ES60601-1, IEC 60601-1-2, IEC 60825-1, IEC 60601-2-22, IEC 62133, ANSI Z80.36-2016).

Technological Characteristics

Solid-state, frequency-doubled laser (532 nm); power 50-1500 mW; pulse 10-2500 ms and CW; spot size 50-1000 µm. Features LED illumination for slit lamps. Connectivity via laser console. Software-controlled interface. Complies with IEC 60825-1 (laser safety) and IEC 60601-1-2 (EMC).

Indications for Use

Indicated for photocoagulation of ocular tissues in patients with eye diseases, specifically retinal photocoagulation, trabeculoplasty, and iridotomy. Prescription use only.

Regulatory Classification

Identification

An ophthalmic laser is an AC-powered device intended to coagulate or cut tissue of the eye, orbit, or surrounding skin by a laser beam.

Predicate Devices

VISULAS green (K181682)

Related Devices

K181682 — VISULAS green · Carl Zeiss Meditec, AG · Mar 6, 2019
K103547 — LIGHTLAS MULTI-WAVELENGTH MEDICAL LASER SYSTEM · Lightmed Corp. · Nov 3, 2011
K960971 — OCULIGHT GL · Iriderm Div. · Aug 28, 1996
K063297 — LIGHTLAS 561 OPTHALMIC PHOTOCOAGULATOR · Lightmed Corp. · Sep 20, 2007
K031665 — IRIS MEDICAL OCULIGHT GL/GLX LASER SYSTEMS · Iridex Corp · Aug 27, 2003

Submission Summary (Full Text)

{0}------------------------------------------------ October 24, 2023 Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and "ADMINISTRATION" in a smaller font size below. Carl Zeiss Meditec Tanesha Bland Sr. Regulatory Affairs Specialist 5300 Central Parkway Dublin, California 94568 ### Re: K232051 Trade/Device Name: VISULAS green Regulation Number: 21 CFR 886.4390 Regulation Name: Ophthalmic Laser Regulatory Class: Class II Product Code: HQF Dated: August 26, 2023 Received: August 28, 2023 ### Dear Tanesha Bland: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). {1}------------------------------------------------ Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Elvin Y. Ng -S Elvin Ng Assistant Director DHT1A: Division of Ophthalmic Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health {2}------------------------------------------------ Enclosure {3}------------------------------------------------ ## Indications for Use 510(k) Number (if known) K232051 Device Name VISULAS green Indications for Use (Describe) VISULAS green is intended for use in photocoagulating ocular tissues of the treatment of diseases of the eve, including - · Photocoagulation of the retina - Trabeculoplasty - · Iridotomy This device is Prescription Use (Rx) only. | Type of Use (Select one or both, as applicable) | |-------------------------------------------------| |-------------------------------------------------| | <input checked="" type="checkbox"/> Prescription Use (Part 21 CFR 801 Subpart D) | |----------------------------------------------------------------------------------| | <input type="checkbox"/> Over-The-Counter Use (21 CFR 801 Subpart C) | #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {4}------------------------------------------------ Image /page/4/Picture/0 description: The image shows the logo for ZEISS. The logo consists of the word "ZEISS" in a bold, sans-serif font. The text is white and is set against a solid blue background. The blue background is in the shape of a rectangle with a curved bottom edge. In accordance with 21 CFR 807.87(h) and (21 CFR 807.92), the 510(k) Summary for VISULAS green is provided below. #### 1. SUBMITTER | Applicant: | Carl Zeiss Meditec, Inc. 5300 Central Parkway Dublin, CA USA | |-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Primary Correspondent: | Tanesha Bland Sr. Regulatory Affairs Specialist Carl Zeiss Meditec, Inc. 5300 Central Parkway Dublin, CA 94568 (925) 216-7963 Phone (925) 557-4259 Fax E-mail: tanesha.bland@zeiss.com (preferred) | | Development Center Contact: | Dr. Ling Ren Regulatory Affairs Manager Carl Zeiss Meditec AG Goeschwitzer Strasse 51-52 Jena, Germany 07745 E-mail: ling.ren@zeiss.com (preferred) | Date Prepared: October 12, 2023 {5}------------------------------------------------ Image /page/5/Picture/0 description: The image shows the logo for Zeiss, a German manufacturer of optical systems and optoelectronics. The logo consists of the word "ZEISS" in a bold, sans-serif font. The text is white and is set against a solid blue background. The bottom of the blue background has a curved shape. #### 2. SUBJECT DEVICE | Device Trade Name: | VISULAS green | |--------------------|--------------------------------------| | 510(k) Number: | K232051 | | Classification: | 21CFR886.4390 Optic Ophthalmic laser | | Regulatory Class: | II | | Product Code: | HQF | | Common Name: | Laser, Ophthalmic | #### 3. PREDICATE DEVICE | Predicate Device: | VISULAS green | |-------------------|--------------------------------------| | 510(k) Number: | K181682 | | Classification: | 21CFR886.4390 Optic Ophthalmic laser | | Regulatory Class: | II | | Product Code: | HQF | #### DEVICE DESCRIPTION 4. VISULAS green is an ophthalmic laser used for standard photocoagulation treatments of ocular tissue with 532 nm wavelength. VISULAS green is operated in single-spot mode or in multi-spot mode. VISULAS green consists of a laser console, touch control panel, optional laser light applicators such as laser slit lamp or laser indirect ophthalmoscope, foot switch and instrument table. The device can also be used with various accessories, such as SL Imaging Solution, contact lenses or Applanation Tonometer. #### ട. INDICATIONS FOR USE VISULAS green is intended for use in photocoagulating ocular tissues in the treatment of diseases of the eye, including - Photocoagulation of the retina - Trabeculoplasty - Iridotomy This device is Prescription Use (Rx) only. #### SUBSTANTIAL EQUIVALENCE TO PRIMARY PREDICATE 6. {6}------------------------------------------------ Image /page/6/Picture/0 description: The image contains the logo for ZEISS. The logo consists of the word "ZEISS" in a bold, sans-serif font, with the letters in white against a solid blue background. The logo is simple and modern, with a clean and professional look. Page 3 of 6 ## Table 1. Subject to Predicate Device Comparison Table – Indications for Use | | VISULAS green | VISULAS green | |---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | K number | K232051 | K181682 | | Legal manufacturer | Carl Zeiss Meditec AG | Carl Zeiss Meditec AG | | Indications for Use Statement | VISULAS green is intended for use in photocoagulating ocular tissues in the treatment of diseases of the eye, including • Photocoagulation of the retina • Trabeculoplasty • Iridotomy | The VISULAS green is intended for use in photocoagulating ocular tissues in the treatment of diseases of the eye, including -Photocoagulation of the retina -Trabeculoplasty for treatment of glaucoma -Iridotomy for treatment of glaucoma | | General laser Specifications | | | | Laser type | solid state laser, frequency-doubled | solid state laser, frequency-doubled | | Wavelength | 532 nm | 532 nm | | Power (cw laser) | 50 to 1500 mW | 50 to 1500 mW | | Length of pulse | 10 - 2500 ms and cw | 10 - 2500 ms and cw | | Repeat mode | yes | yes | | Laser spot size settings | 50 µm to 1000 µm | 50 µm to 1000 µm | | Aiming beam | 620 - 650 nm | 620 - 650 nm | | Types of laser applicators | LSL, laser endoprobes, LIO | LSL, VISULINK 532/U, laser endoprobes, LIO | | Multi-spot treatment mode | yes | yes | | Increments of power | 50-200 mW (10 mW steps), 200- 500 mW (20 mW steps), 500-1500 mW (50 mW steps) | 50-100 mW (10 mW steps), 100- 1500 mW (50 mW steps) | | Laser spot size settings | Continuously adjustable from 50 µm to 1000 µm | 50 µm,100 µm, 200 µm, 300 µm, 500 µm, 1000 µm | | Conditions of Use | | | | Site in the body | eye | eye | | Principle of operation | Photocoagulation of ocular tissue | Photocoagulation of ocular tissue | {7}------------------------------------------------ Image /page/7/Picture/0 description: The image shows the logo for Zeiss, a German manufacturer of optical systems and optoelectronics. The logo consists of the word "ZEISS" in a bold, sans-serif font. The text is white and is set against a solid blue background. The blue background is in the shape of a rectangle with a curved bottom edge. ### Table 2. Subject to Predicate Device Comparison Table - Laser Slit Lamps The Laser Slit Lamps (LSL) are optional components of the subject device VISULAS green (K232051) and the predicate device VISULAS green (K181682). | | LSL green classic, LSL green comfort | LSL green classic, LSL green comfort | |---------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------| | | | | | K number | Component of subject device VISULAS green (K232051) | Component of predicate device VISULAS green (K181682) | | Legal manufacturer | Carl Zeiss Meditec AG | Carl Zeiss Meditec AG | | Design | | | | Slit lamp type | ZEISS type | ZEISS type | | Tube system | Parallel or convergent | Parallel or convergent | | Power supply | Via laser console | Via laser console | | Specifications | | | | Slit width | 0 mm to 14 mm (continuously) | LSL green classic: 0.2 mm / 0.6 mm / 1.6 mm / 4.4 mm / 15.0 mm LSL green comfort: 0 mm to 14 mm (continuously) | | Slit length | 1/3/5/9/14 mm | LSL green classic: 1/3/5/7/10/12/14/15 mm LSL green comfort: 1/3/5/9/14 mm | | Slit image rotation | 0°, ±45°, 90° | 0°, ±45°, 90° | | Magnification | LSL green classic: 3 magnifications in steps of 8x, 12x, 20x LSL green comfort: 5 magnifications, in steps of 5x, 8x, 12x, 20x, 32x | LSL green classic: 3 magnifications in steps of 8x, 12x, 20x LSL green comfort: 5 magnifications, in steps of 5x, 8x, 12x, 20x, 32x | | Light source | LED illumination, continuously adjustable brightness | Halogen 12V/30W, brightness continuously adjustable | | Micromanipulator | LSL green classic: no LSL green comfort: yes | LSL green classic: no LSL green comfort: yes | The VISULAS green and predicate devices are both intended as ophthalmic lasers for photocoagulation. The indications for use are within the same intended use as the predicate devices and do not raise different questions of safety and effectiveness. The primary differences between the subject device, VISULAS green (K232051), and the predicate device, VISULAS green (K181682), are listed in the following table with corresponding justification as to why the changes do not affect the safety and effectiveness of the subject device. {8}------------------------------------------------ Image /page/8/Picture/0 description: The image shows the word "ZEISS" in white letters on a blue background. The word is in a bold, sans-serif font. The blue background is a square shape with a curved bottom edge. The logo is simple and modern. Page 5 of 6 ### Table 3. Differences between the subject device and the predicate device and justification of no impact on safety and effectiveness | Differences between the subject device and the predicate device | Justification of no impact on safety and effectiveness | |----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | The illumination source of the Laser Slit Lamps is changed from halogen lamp to LED. | The subject device went through the same Verification and Validation Process as the predicate device and passed the applicable testing. | | The slit width of LSL green classic is changed from available in 5 steps to continuously adjustable 0 – 14 mm. | The slit width of LSL green classic is now the same as that of LSL green comfort. The subject device went through the same Verification and Validation Process as the predicate device and passed the applicable testing. | | The slit length of LSL green classic is changed from available in 8 steps to available in 5 steps. | The slit length of LSL green classic is now the same as that of LSL green comfort. The subject device went through the same Verification and Validation Process as the predicate device and passed the applicable testing. | | New color scheme of the outer parts is applied. | The subject device went through the same Verification and Validation Process as the predicate device and passed the applicable testing. | | The guidelines of ZEISS User Interface are applied to the software. | The subject device went through the same Verification and Validation Process as the predicate device and passed the applicable testing. | | The Instructions for Use is updated to reflect the changes and to adapt to the editorial scheme. | The subject device went through the same Verification and Validation Process as the predicate device and passed the applicable testing. | | Changes to tackle obsolescence issues. | The subject device went through the same Verification and Validation Process as the predicate device and passed the applicable testing. | The VISULAS green subject device and the predicate laser systems have minor parameter differences but share the same fundamental principle of operation: Photocoagulation: Continuous wave operation in which thermal energy created by the absorption of the laser energy by the ocular tissue is causing coagulation. The subject VISULAS green is substantially equivalent to the predicate laser systems presented in the 510(k) premarket notification in terms of indications for use and technological characteristics. Differences between subject device and predicate devices do not raise any new issues of safety or effectiveness. {9}------------------------------------------------ Image /page/9/Picture/0 description: The image features the word "ZEISS" in bold, white letters against a solid blue background. The letters are stacked vertically, with the word "ZEISS" taking up the majority of the space. Below the word, there is a curved white line, suggesting a stylized representation of a lens or optical element, which is a common visual element associated with the Zeiss brand. #### 7. SUMMARY OF STUDIES ### Biocompatibility Testing Biocompatibility testing was performed on the appropriate components of the subject device. The testing performed aligns with current recognized standards and meets or exceeds testing performed on the predicate device. Biocompatibility testing demonstrated equivalency between the subject device and the predicate device. ## Laser safety, electrical safety and electromagnetic compatibility (ENC) VISULAS green was evaluated against the following requirements and was found to comply with: - · ANSI/AAMI ES60601-1:2005/(R) 2012 - ANSI Z80.36-2016 - · IEC 60601-1-2:2014 - · IEC 60825-1:2007 - IEC 60601-2-22:2012 - · IEC 62133: 2012 # Software Verification and Validation Testing The software of this device is considered as a "Major" level of concern. Software verification and validation testing was conducted, and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." Verification and validation of VISULAS green demonstrated that the product works as designed. ### Bench Testing Non-clinical system testing provided an evaluation of the system relevant to each of the system specifications. The functional and system level testing showed that the system met the defined specifications. ZEISS demonstrated non-clinical equivalency between the subject device and the predicate device. # Animal Testing Not applicable. Animal studies are not necessary to establish the substantial equivalence of this device. # Clinical Data Not applicable. Clinical studies are not necessary to establish the substantial equivalence of this device. #### CONCLUSION 8. The VISULAS green is substantially equivalent to the predicate device, VISULAS green (K181682). The VISULAS green is similar in technological characteristics, performance, principles of operation, and has identical indications for use as the predicate device. Any differences between the proposed device and the predicate devices do not raise any new issues of safety or effectiveness. Thus, the VISULAS green is substantially equivalent to the predicate devices.